Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

Jazz Pharma has agreed to pay $145 million to settle lawsuits claiming it illegally acted to prevent generic versions of its ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in ...

Xyrem (sodium oxybate) may not be safe to take while pregnant or breastfeeding. Certain factors, including the risk of not treating your condition during pregnancy, may determine whether you ...

This is a practice very common among cancer drugs. Other than the reputation and infamous notoriety of the drug, Xyrem had another drawback. It contains 109% of the American Heart Association’s ...

In a high-stakes twist in the pharmaceutical legal arena, Jazz Pharmaceuticals has agreed to shell out a staggering $145 million to settle claims that it orchestrated an anticompetitive scheme with ...

"His proven track record in driving commercial success for novel, first-in-class products like XYREM ® will be an asset in realizing the significant commercial potential of MM120. As we approach ...

Subject to court approval, the settlement will bring an end to class action lawsuits initiated by several Xyrem buyers who accused Ireland-based Jazz (NASDAQ:JAZZ) of reaching illegal patent ...

Xyrem, a medication approved in the U.S., is used for the treatment of excessive daytime sleepiness and sudden loss of muscle control in patients suffering from narcolepsy, a chronic neurological ...